HHLR Advisors’s Pyxis Oncology PYXS Stock Holding History

HHLR Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-382,606	Closed	-$597K	–	54
2024 Q4	$597K	Hold	382,606	–	–	0.02%	41
2024 Q3	$1.4M	Hold	382,606	–	–	0.03%	39
2024 Q2	$1.27M	Hold	382,606	–	–	0.03%	67
2024 Q1	$1.63M	Hold	382,606	–	–	0.04%	53
2023 Q4	$689K	Hold	382,606	–	–	0.01%	45
2023 Q3	$761K	Hold	382,606	–	–	0.02%	53
2023 Q2	$979K	Sell	382,606 -148,086	-28%	-$470K	0.02%	54
2023 Q1	$2.13M	Sell	530,692 -233,714	-31%	-$467K	0.04%	60
2022 Q4	$1.02M	Hold	764,406	–	–	0.02%	62
2022 Q3	$1.51M	Hold	764,406	–	–	0.04%	56
2022 Q2	$1.82M	Hold	764,406	–	–	0.04%	59
2022 Q1	$3.09M	Hold	764,406	–	–	0.06%	53
2021 Q4	$8.39M	Buy	+764,406	New	+$8.75M	0.13%	53

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Laurion Capital Management New York $1.07B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return